MedTrace Logo

Vitamin D Supplementation in Obesity and Weight Loss (3DD Study)

NCT01631292 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2023-11-22

No results posted yet for this study

Summary

In this study, we will provide supplemental vitamin D in postmenopausal overweight/obese women, and hypothesize that it will not affect areal BMD, but will alter bone compartments (trabecular and cortical bone). In addition, higher vitamin D intake will increase serum 25OHD and suppress serum PTH and bone turnover during weight reduction. Secondary outcomes include the influence of vitamin D and weight loss on markers of insulin resistance and on cognitive tests of attention, learning, and memory.

Conditions

Interventions

DIETARY_SUPPLEMENT

600 IU Vitamin D3

Once daily

DIETARY_SUPPLEMENT

2000 IU Vitamin D3

Once daily

DIETARY_SUPPLEMENT

4000 IU Vitamin D3

Once daily

Sponsors & Collaborators

  • Rutgers University

    lead OTHER

Principal Investigators

  • Sue Shapses, PhD · Rutgers University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
72 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2015-05-31
Completion
2019-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01631292 on ClinicalTrials.gov